Surface receptors in Golgi acquire their specific oligosaccharide structure and composition, which would be recognized as a signal for their transport to the plasma membrane. Tumor cells, including gliomas, have an AbMole BioScience altered pattern of protein glycosylation compared to normal cells due to the modifications of glycosylation machinery in the Golgi apparatus. As mentioned above, CD150 colocalization with Golgi marker was significantly lower in glioma cells in comparison to B cell line. Therefore, in glioma cells CD150 glycosylation could be insufficient or altered leading to the lack of its surface expression on the plasma membrane. This is supported by our results of western blot analysis that showed differences in the pattern of CD150 protein bands between glioma and B cells with preferential expression of bands with lower molecular weight in glioma cells. In MP-1 cell line the band of 40 kDa corresponds to non-glycosylated protein core of mCD150. Moreover, multiple bands in glioma cells may correspond to different CD150 isoforms , and/or previously not identified CD150 splice variants. Our data also reveal another aspect of CD150 expression in glioma cells. Due to the lack of CD150 cell surface expression, glioma cell lines are resistant to wild type MV entry and consequent oncolysis. Potential promotion of CD150 vertical segregation from intracellular storage compartments in glioma cells could open new perspectives for CD150-targeted, MV based oncolytic therapy of CNS tumors. Furthermore, utilization of retargeted MV, already used in clinical assays, allows virus entry into tumor cells, and may potentially lead to the interaction between MV hemagglutinin with intracellular CD150 and consecutive signaling. Indeed, recent report underlined the importance of CD150 signaling in the MV-induced tumor regression. In this context, it is important to explore aspects of CD150 functions in glioma cells that is the subject of our current studies. Despite the progress in discovery of novel glioma biomarkers, there is an urgent need for additional objective molecular markers that will help to refine the histomolecular classification of CNS tumors. Our VE-821 studies revealed a novel CD150 isoform that is a specific feature of primate genomes and is a new potential molecular marker of CNS tumors. Broad studies of CD150 expression in CNS tumors in conjunction with evaluation of clinical outcomes will give an answer whether CD150 expression could be used as a reliable diagnostic, prognostic and predictive marker, as well as a target for the CNS tumors therapy. Preservation of the biological diversity of any ecosystem is essential for evaluation of the distribution and connectivity of its populations and the factors that determine these patterns.